Medicus Pharma said it has received authorization in the United Arab Emirates to move ahead with a Phase 2a clinical study of Teverelix for endometriosis. The approval came from the Department of Health – Abu Dhabi, which granted Investigational New Drug authorization for the company’s PRECISION-E2 study.
According to the announcement, the trial will evaluate Teverelix in women with moderate-to-severe endometriosis. The regulatory clearance is an important development step because it allows the study to proceed in the UAE under the approved investigational framework.
Endometriosis is a condition that can cause significant pain and other complications, making new treatment research a closely watched area in women’s health. By advancing PRECISION-E2, Medicus Pharma is continuing clinical work around Teverelix as it seeks more data on the therapy in this patient group.
The update also marks a milestone for the company’s broader development program. For investors and healthcare observers following Medicus Pharma, the Abu Dhabi IND authorization signals that the Teverelix Phase 2a endometriosis study has cleared a key regulatory hurdle.
